Revenue
Total Revenue
Gilead Sciences Total Revenue decreased by 12.2% to $6.96B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.4%, from $6.67B to $6.96B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows relatively stable performance with a 1.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionRevenue
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026
How to read this metric
An increase indicates growing market demand or successful price increases, while a decrease suggests market saturation or competitive pressure.
Detailed definition
The total amount of income generated by the sale of goods or services related to the company's primary operations. For a...
Peer comparison
Peer technology firms typically report this as Net Sales or Total Revenue, reflecting the scale of their market reach.
Metric ID:
total_revenueHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.22B | $7.42B | $7.24B | $6.59B | $6.26B | $7.04B | $7.39B | $6.35B | $6.60B | $7.05B | $7.11B | $6.69B | $6.95B | $7.55B | $7.57B | $6.67B | $7.08B | $7.77B | $7.93B | $6.96B |
| QoQ Change | — | +19.4% | -2.4% | -9.0% | -5.0% | +12.5% | +4.9% | -14.0% | +3.9% | +6.8% | +0.9% | -6.0% | +4.0% | +8.5% | +0.3% | -11.9% | +6.2% | +9.7% | +2.0% | -12.2% |
| YoY Change | — | — | — | — | +0.7% | -5.1% | +2.0% | -3.6% | +5.4% | +0.1% | -3.7% | +5.3% | +5.4% | +7.0% | +6.4% | -0.3% | +1.8% | +3.0% | +4.7% | +4.4% |
Range$6.22B – $7.93B
CAGR+2.4%
Avg YoY Growth+2.1%
Median YoY Growth+2.5%
Product Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Biktarvy | $3.23B | $3.47B | $3.77B | $3.15B | $3.53B | $3.69B | $3.97B | $3.36B |
| Descovy | $485.00M | $586.00M | $616.00M | $586.00M | $653.00M | $701.00M | $818.00M | $807.00M |
| Trodelvy | — | — | — | $293.00M | $364.00M | $357.00M | $383.00M | $402.00M |
| Yescarta | $414.00M | $387.00M | $389.00M | $386.00M | $393.00M | $349.00M | $367.00M | $332.00M |
| Sofosbuvir/Velpatasvir | — | — | — | $346.00M | $342.00M | $309.00M | $275.00M | $283.00M |
| Genvoya | $440.00M | $449.00M | $470.00M | $364.00M | $377.00M | $377.00M | $380.00M | $264.00M |
| Vemlidy | — | — | — | $252.00M | $252.00M | $280.00M | $286.00M | $237.00M |
| Odefsey | $315.00M | $326.00M | $337.00M | $281.00M | $298.00M | $277.00M | $311.00M | $221.00M |
| Yeztugo | — | — | — | — | — | — | — | $166.00M |
| Veklury | — | — | — | $302.00M | $121.00M | $277.00M | $211.00M | $144.00M |
| AmBisome | $151.00M | $130.00M | $108.00M | $139.00M | $129.00M | $123.00M | $118.00M | $138.00M |
| Symtuza - Revenue share | — | — | — | $114.00M | $124.00M | $124.00M | $133.00M | $138.00M |
| Livdelzi | — | — | — | — | — | — | — | $133.00M |
| Other Liver Disease | — | — | — | $161.00M | $201.00M | $231.00M | $281.00M | $114.00M |
| Tecartus | — | — | — | $78.00M | $92.00M | $83.00M | $91.00M | $75.00M |
| Other HIV | — | — | — | $91.00M | $107.00M | $112.00M | $190.00M | $73.00M |
| Other | $130.00M | $71.00M | $75.00M | $70.00M | $73.00M | $61.00M | $86.00M | $58.00M |
| Royalty, contract and other revenues | $41.00M | $30.00M | $34.00M | $54.00M | $27.00M | $424.00M | $22.00M | $14.00M |
| Total Liver Disease | $832.00M | $733.00M | — | — | — | — | — | — |
| Total Oncology | $841.00M | $816.00M | — | — | — | — | — | — |
| Total | $6.95B | $7.55B | $7.57B | $6.67B | $7.08B | $7.77B | $7.93B | $6.96B |
Geographic Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Europe | $1.13B | $1.17B | $1.18B | $1.08B | $1.19B | $1.56B | $1.24B | $1.14B |
| Rest of World | — | — | — | $915.00M | $842.00M | $933.00M | $813.00M | $889.00M |
| Total | $6.95B | $7.55B | $7.57B | $6.67B | $7.08B | $7.77B | $7.93B | $6.96B |
Total Revenue at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's total revenue?
- Gilead Sciences (GILD) reported total revenue of $6.96B in Q1 2026.
- How has Gilead Sciences's total revenue changed year-over-year?
- Gilead Sciences's total revenue increased by 4.4% year-over-year, from $6.67B to $6.96B.
- What is the long-term trend for Gilead Sciences's total revenue?
- Over 4 years (2021 to 2025), Gilead Sciences's total revenue has grown at a 1.9% compound annual growth rate (CAGR), from $27.31B to $29.44B.
- What does total revenue mean?
- The total amount of money a company brings in from selling its products and services.